In Brief: Rogaine Rx-to-OTC switch
Rogaine Rx-to-OTC switch: Upjohn's NDA for switch of minoxidil from prescription to OTC status as a hair regrowth treatment for androgenetic alopecia scheduled to be considered by FDA's Nonprescription Drug Dermatologic Drugs Advisory Committees on Nov. 17. NDAC will meet on Nov. 16 with the Pulmonary-Allergy Drugs Advisory Committee to review Sandoz' clemastine fumarate IND for efficacy in the common cold. On the same day NDAC will discuss a meta-analysis of antihistamines and the common cold and discuss inclusion of the common cold as an indication in the OTC final monograph for antihistamines. The meeting will be held beginning at 8 a.m. in conference rooms D & E of FDA's Parklawn Building...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.